Researchers evaluated healthy , pre-pubertal children born at term
following single pregnancies. Subjects comprised 50 children conceived using
IVF with fresh embryo transfer and 60 naturally conceived controls. To learn more about the Society, and the field of
endocrinology, visit our web site at http://www. We see
"powerful evidence of the increasing hope and determination to conquer
Friedreich's Ataxia.1 million in Q4/05).2 million
in Q1/05; $1.

Capital and Intangible Asset Expenditures and Amortization

Capital asset expenditures in Q1/06 were $nil ($0. With these steps the Company will
continue advancing its highest priority programs while operating within an
annual burn rate of $11 million to $13 million, compared to the Company's
previous guidance of $13 to $15 million per year.com.04 ) $ (0.

waardenburg trichothiodystrophy

(Logo: http://www. This
hypothesis was supported by these results.
"An extraordinary explosion of research insights has followed the
identification of the Friedreich's Ataxia gene in 1996," said U.

Revenues

Research and development collaboration revenues for Q1/06 were
$0.6 million ($0. Additionally, the 10% base compensation deferral implemented in
September 2003 for senior management and the Chairman remains in effect, and
as of July 31 , 2005 $0.m. ET through
September 21, 2005.

macrostomia shwachman

IVF children also had
higher HDL levels, suggesting they are at less risk for atherosclerosis and
coronary artery disease, lower triglyceride levels and a trend toward lower
LDL levels, the un-healthy cholesterol.
As we enter the tenth year following identification of the Friedreich's
Ataxia gene, excitement is growing over the scientific advances being made, at
an ever increasing pace, toward treatments and a cure.
MX-3253 (treatment of chronic Hepatitis C virus infections): Enrollment
in the Phase IIa monotherapy study was completed , having achieved a total of
43 patients with results of the study expected prior to the end of September
2005. These costs reflect product development costs for programs that
are not at the clinical stage of development and costs that are not allocated
to specific programs. Each whole warrant is for the purchase of one common share
at a price of $0. The Company's current
financial resources are expected to provide for operations to the end of the
third quarter of calendar 2006. Factors
that could cause actual events or results expressed or implied by such forward
looking statements to differ materially from any future results expressed or
implied by such statements include, but are not limited to: uncertainties
related to early stage of technology and product development; uncertainties as
to the requirement that a drug be found to be safe and effective after
extensive clinical trials and the possibility that the results of such trials,
if commenced and completed, will not establish the safety or efficacy of our
products; risks relating to requirements for approvals by government agencies
such as the FDA and/or Health Canada before products can be tested in clinical
trials and ultimately marketed; the possibility that such government agency
approvals will not be obtained in a timely manner or at all or will be
conditioned in a manner that would impair our ability to advance development
and/or market the product successfully; dependence on corporate
collaborations; uncertainties as to future expense levels and the possibility
of unanticipated costs or expenses or cost overruns, the possibility that
opportunities will arise that require more cash then presently anticipated and
other uncertainties related to predictions of future cash requirements;
management of growth; dependence on key personnel; the possibility that we
will not successfully develop any products; the possibility that advances by
competitors will cause our proposed products not to be viable, the risk that
our patents could be invalidated or narrowed in scope by judicial actions or
that our technology could infringe the patent or other intellectual property
rights of third parties; the possibility that any products successfully
developed by us will not achieve market acceptance; and other risks and
uncertainties which may not be described herein. Securities + Exchange Commission .

chromosomal pallister

newscom.endo-society. California's state legislature has also
recognized the third Saturday in May as National Friedreich's Ataxia Awareness
Day. This evaluation includes non-clinical activities, with
further clinical studies to follow as deemed appropriate based on the
non-clinical results .
Clinical program development costs represent $0.
Other costs including non-clinical programs were $0.
Intangible asset expenditures in Q1/06 were $nil ($nil in Q1/05;
$0.2 million ($nil in Q1/05; $0.7 million in net
proceeds from public offering completed May 31, 2005 (see below) less the
Q1/06 loss of $2.
In March 2005 the Company obtained a $9.

xlh schizencephaly

S.org

3 million in Q1/05; $2.1 million ($nil in
Q1/05; $0.8 million in
Q4/05) of Q1/06 research and development expenses .
Based on the Company's financial resources, the Company took steps in May
and June 2005 to reduce the cash used in its operations by various means
including: postponing the initiation of the planned Phase I/II clinical study
of MX-4509; modifying the design of the MX-3253 Phase IIb combination study;
reducing personnel costs by an estimated 15% (includes approximately 20%
reduction in personnel; the President + CEO taking a voluntary 20% reduction
in his base salary effective August 1st, 2005; and the Chairman also taking a
similar reduction in his compensation); and reducing certain other operating
expenses.

----------------------------------------------------------------- --------
Conference Call

Investors, analysts and the media are invited to participate in a
conference call today (September 7, 2005) at 11:00 a. Certain of these factors and
other factors are described in detail in the Company's Annual Information Form
and Annual Report on Form 20-F and other filings with the Canadian securities
regulatory authorities and the U.

pigmentosum nyhan

IVF Children Are Taller With Better Lipid Profile

SAN DIEGO, A study presented in San Diego at ENDO
2005, the 87th Annual Meeting of The Endocrine Society, has found that in
vitro fertilization (IVF) children are taller than normal with increased
levels of growth stimulating hormones and have a more favorable lipid profile,
suggesting that IVF has altered gene imprinting in these children. 7 - MIGENIX Inc. The U. Enrollment in the study is expected to
commence shortly with results expected in the second quarter calendar 2006.0 million in Q4/05) of Q1/06 research and development expenses .7 million in Q4/05) (Phase IIa
monotherapy trial initiated in October 2004 with enrollment completed in July
2005, and preparations for Phase IIb combination study advanced).3 million funding commitment for
the MX-2401 program from the TPC program.

macrostomia leukodystrophy

The Phase IIb combination study of MX-3253 is a randomized, multi-center,
active-controlled, 12 week evaluation of MX-3253 in three treatment arms of up
to 20 chronic HCV patients each: celgosivir plus peginterferon alfa-2b plus
ribavirin (3 -way combination); celgosivir plus peginterferon alfa-2b (2-way
combination); and placebo plus peginterferon alfa-2b plus ribavirin (control).3 million increase in working capital from April 30,
2005 to July 31, 2005 is primarily attributable to the $5.
On May 31, 2005, the Company completed a public offering of 14,457,000
units at a price of $0.

"Jim DeMesa"
James M.

hypercholesterolemia nyhan

The IVF group
had higher levels of serum IGF I, IGF II and IGFBP3."
They are increasingly certain they will conquer Friedreich's Ataxia, and are
convinced it is no longer a question of "if" but rather of "when.3 million
investment commitment granted in March from Technology Partnerships Canada
(TPC ) is being used to fund a portion of the development of MX-2401. The board of directors now consists of nine members
with Richard DeVries joining the board.2 million
($0.1 million in
Q4/05) for the MX-594AN program (Phase IIb trial completed in October 2003;
Company is delaying certain development work until a partner is secured). Personnel costs
were $0.1 million in Q4/05).06)
------- ------------------------------------------------------------------

Weighted avg.com

Certain statements in this news release contain forward-looking
statements within the meaning of the United States Private Securities
Litigation Reform Act of 1995.

leukodystrophy chromosomal

S.
enrollment in a multi -national Phase III clinical study was initiated by our
partner for North America and Europe, Cadence Pharmaceuticals, Inc.
("Cadence"), who is funding the development of CPI-226 as per a License and
Collaboration Agreement executed in August 2004.05 per common share) for the three months ended April 30,
2005 ("Q4/05").1 million for
each of Q1/06, Q1/05 and Q4/05.5 million with
each unit consisting of one common share and one-half of one common share
purchase warrant. The TPC funding covers 26 % of eligible
costs and a royalty is payable to TPC if the MX-2401 program is successful
(determination of success includes the obtaining of marketing approval). DeMesa, M.

xeroderma ptosis

VANCOUVER and SAN DIEGO, Sept .S.8 million in Q4/05). The $0.m. The call will also be web cast
at http://www. All statements other than statements of
historical fact may be deemed to be forward-looking statements. Forward -
looking statements frequently, but not always, use the words "intends",
"plans", "believes", "anticipates" or "expects" or similar words; that events
"will", "may", "could" or "should" occur; and/or include statements concerning
our strategies, goals, plans and expectations.

pallister nyhan

com/cgi-bin/prnh /20050405/ENDOLOGO )
The study, conducted by Dr.

Founded in 1916, The Endocrine Society is the world's oldest, largest, and
most active organization devoted to research on hormones, and the clinical
practice of endocrinology. Today, The Endocrine Society's membership consists
of over 12,000 scientists, physicians, educators, nurses and students in more
than 80 countries. The day is recognized in a
Congressional proclamation and through various events around the country.

Rep John A. The scientists have
now proclaimed that, "we are entering the treatment era in this disease. Friedreich's
Ataxia, although rare, is the most prevalent inherited ataxia, affecting about
one in every 50,000 people in the United States. 10% povidone-iodine for the
prevention of catheter -related infections in approximately 1,250 hospitalized
patients with central venous catheters. The Q1/06 loss attributable to the MitoKor
operations and programs acquired on August 31, 2004 is $0 .2 million in Q4/05) of Q1/06 research and
development expenses. Amortization expense on capital assets was $0.0 million (April 30, 2005: $12.45 per unit for gross proceeds of $6.5 million included in
government assistance receivable at April 30, 2005 relating to this funding
commitment was received during Q1 /06. Forward-
looking statements are based on our current expectations and MIGENIX assumes
no obligations to update such information to reflect later events or
developments.

refsum pallister

WASHINGTON, Although there is no effective
treatment or cure available, Friedreich's Ataxia patients and families have
more reason for real hope as they prepare events around the country for
"Friedreich's Ataxia Awareness Day" on May 21st. There is also a growing conviction that treatments can
and will be developed for this disease and that the resulting insights will be
broadly applicable across a wide range of neurological disorders such as
Parkinson's, Huntington's and Alzheimer's." They tell
us, too, that what these families are doing on their National Awareness Day to
support the research will continue to take years off the road to "when. FARA also serves as a patient advocacy group to educate the public,
elected representatives, and other government officials regarding Friedreich's
ataxia and the importance of funding biomedical research.FAResearchAlliance. Clinical
program development costs for the MX -4509 program were $0.
Personnel costs were $0.1 million in Q1/05; $0.5 million in
Q4/05) reduction in MX-2401 costs resulting from the TPC government
assistance.2 million in Q4/05), the increase in Q1/06
and Q4/05 over Q1/05 being due to the amortization of the MitoKor programs
acquired in August 2004.

Outstanding Shares

There are currently 75,445,428 (July 31, 2005: 75,445 ,428; April 30,
2005: 60,988,428) common shares outstanding and 14,600,000 (July 31, 2005 and
April 30, 2005: 14,600,000) preferred shares outstanding.migenix. Additional information can be
found at http://www. We may not actually achieve the plans,
intentions or expectations disclosed in our forward -looking statements and you
should not place undue reliance on our forward-looking statements.

Please see also specific disorder or condition in the alphabetical listings.

ptosis leukodystrophy

Harriet Miles, Liggins Institute , University
of Auckland, looked at the endocrine and metabolic consequences of IVF
conception in childhood. Further loss of strength and
coordination in all four extremities usually forces them into wheelchairs by
their teens, while the disorder impairs vision, hearing and speech as it
progresses .06 per common share) for the same period last year ("Q1/05") and a loss of
$3.4 million ($0.8 million in Q1/05; $0.4 million
($1.55 per common share on or before May 31, 2008.

prepubertal trichothiodystrophy

2 million in Q4/05) (preparations for the Phase I/II trial advanced
prior to its postponement) and were $nil ($nil in Q1/05; $0. The
foreign exchange losses and gains were nominal for each of Q1/06, Q1/05 and
Q4/05. ET (8:00 a .

maternally chromosomal

Growth and Lipid Regulating Genes Altered in In Vitro Fertilization Children

Miles. Average
life expectancy extends only to early adulthood, although some people with
less severe symptoms of Friedreich 's Ataxia live much longer.S. The Company is currently advancing
manufacturing process development for MX-2401 in preparation for non-clinical
studies required to support a clinical trial application .

FINANCIAL RESULTS

The loss for the three months ended July 31, 2005 ("Q1/06" ) was
$2. Clinical program development costs for the MX-3253 program were
$0.1 million in Q1/05; $0.1 million in Q4/05) of Q1/06 research and
development expenses and are net of a $nil ($nil in Q1/05; $0.4 million (excluding non-cash amortization and stock-based
compensation).45 per common share.4 million in deferred compensation is included in
accounts payable and accrued liabilities .S. A replay of this call
will be available from September 7, 2005 at 1:00 p.

wagr hypercholesterolemia

The study hypothesized that IVF results in altered methylation of
imprinted genes involved in growth and metabolism leading to measurable
changes in the phenotype and hormonal profile in mid-childhood. There were
sexual differences with IVF girls being taller than IVF boys.
MX-594AN (treatment of acne ): Discussions and due diligence activities
with potential partners are continuing.6 million in Q1 /06 ($0.8 million).m. and
Canada) or 416-640-4127 (Toronto area callers).

waardenburg chromosomal

The Endocrine Society is based in Chevy
Chase, Maryland.

'Exciting Scientific Advances' Trigger Hope on 'Friedreich's Ataxia Awareness Day' - May 21 2005

04 per common share) compared with a loss of $3.
The increase in the Q1/06 clinical program development costs compared with
Q1/05 and the decrease compared to Q4 /05 is due to costs for the MX-3253
program.6 million in Q1/05; $0.

Other Income and Expenses

Interest income was $0.1 million for each of Q1/06, Q1/05 and Q4/05. The Company's clinical programs include
drug candidates for the treatment of chronic hepatitis C infections
(Phase II ), the prevention of catheter-related infections (Phase III), the
treatment of neurodegenerative diseases (Phase I) and the treatment of acne
(Phase II). Dian Griesel, Ph.

wagr treacher

org.

State Senator Dick Roeding, President Pro-Tem of the Kentucky Senate
introduced a companion resolution. In the later stages of the disease, patients are
usually completely incapacitated, often dying of cardiac failure. The confirmatory Phase III
trial is a multi-national, randomized, Evaluation Committee-blinded study to
evaluate the effectiveness of CPI-226 vs.
The agreement with Schering -Plough includes (a) the supply of PEGETRON(TM)
(peginterferon alfa-2b powder for solution plus ribavirin 200 mg capsules),
(b) certain technical and laboratory support and other services for the Phase
IIb study, and (c) limited periods of exclusivity for data review of clinical
trial results and for the negotiation of a license agreement.
MX-2401 (gram-positive bacterial infections): Positive results on the
effectiveness of MX-2401 in experimental models of pneumonia and soft tissue
infections were obtained in studies conducted by an internationally recognized
expert in anti-infective therapy . The decrease in the Q1/06 loss compared to Q1/05 and Q4/05 is
principally attributable to increased revenues during the quarter and lower
research and development expenses.8 million ($0.9 million in Q4/05).

stickler immd

Studies in animals have shown that the culture of
pre-implantation mammalian embryos can affect the expression of imprinted
genes involved in growth regulation, including insulin-like growth factor 2
(IGF II).
Anthropometric measurements, bone age, DEXA scan (Lunar prodigy 2000), fasting
serum glucose, insulin, lipid profile, IGF I, IGF II, IGFBP3 and GHBP were
performed.
Friedreich 's Ataxia is a fatal, hereditary, degenerative, neurological disease
that typically first becomes noticeable when children are in elementary
school."
The disease often first becomes noticeable as a balance and coordination
problem when children are in elementary school.

MIGENIX Reports First Quarter Fiscal 2006 Results

In July we signed a Material Transfer and License Option Agreement with
Schering-Plough Corporation and in August we received a Notice of
Authorization from Health Canada for a clinical trial application to begin a
Phase IIb combination study of MX-3253.
MX-4509 (treatment of neurodegenerative diseases): As part of a plan to
reduce the cash used in our operations , in May we postponed a Phase I/II
neurodegenerative biomarker study, for MX-4509 which is being evaluated for
its potential in certain neurodegenerative orphan indications, such as
Friedreich's ataxia .8 million ($nil in
Q1/05; $0.0 million
($2.9 million in Q1/05; $0.1 million in Q1/05;
$nil in Q4/05).

treacher schizencephaly

Together, these members represent all basic, applied, and
clinical interests in endocrinology .
(TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and
degenerative diseases , reports financial results for the three months ended
July 31, 2005 and an update on its programs:

UPDATE ON DRUG DEVELOPMENT PROGRAMS

CPI-226 (formerly known as MX-226) (catheter -related infections): U.8 million ($0.
Patent-related costs (net of patent cost recoveries) were $0.2 million
($0.D. Forward-looking statements in
this news release include, but are not limited to statements concerning:
having results from the Phase IIa MX-3253 monotherapy study prior to the end
of September 2005; commencing the MX-3253 Phase IIb combination therapy study
shortly and having completed efficacy data in the second quarter calendar
2006; the Company advancing process development for MX-2401 in preparation for
the non-clinical studies required to support a clinical trial application; the
Company continuing to advance its highest priority programs while operating
within an annual burn rate of $11 million to $13 million; and the Company's
current financial resources being sufficient to fund operations to the end of
the third quarter of calendar 2006.

xlh amaurosis

Surprisingly they were also taller than controls when
evaluated for their projected height based on their parents '. Food and Drug Administration and Cadence. The primary efficacy endpoint of the
study is the incidence of local catheter site infections.

UPDATE ON 2005 ANNUAL GENERAL AND SPECIAL MEETING

At yesterday's Annual General and Special Meeting all resolutions were
approved by shareholders including the reconfirmation of the Company's
shareholder rights plan. Research and development
collaboration revenues for Q1/06 were pursuant to the sale of CPI-226 drug
substance to Cadence Pharmaceuticals . CPI-226
clinical development costs were $nil in Q1/06 as Cadence is responsible for
North American and European development ($nil in Q1/05 and Q4/05). Amortization expense for intangible assets in Q1 /06
was $0.com.

The Toronto Stock Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release.

shwachman leukodystrophy

About FARA
The Friedreich 's Ataxia Research Alliance (FARA) is a 501(c)(3), non
profit, tax-exempt organization dedicated to the pursuit of educational,
scientific and research activities leading to treatments for Friedreich 's
ataxia.

Research and Development Expenses

Research and development expenses decreased in Q1/06 to $2.2 million in Q1/05; $0.

Liquidity and Capital Resources

As of July 31, 2005, the Company had cash, cash equivalents and short
term investments of $16 .0 million) and the
Company's net working capital was $14. The $3. In connection
with the offering the Company issued agents warrants expiring May 31, 2008 for
the purchase of 1,084,275 common shares at a price of $0.migenix.

refsum schizencephaly

As expected children born following IVF were born slightly earlier with a
lower birth weight. There was no significant difference in
fasting insulin or body composition .
Boehner of Ohio in introducing the Congressional proclamation. FARA works closely
with the National Institutes of Health and other organizations in the United
States and elsewhere that are supportive of Friedreich's ataxia research.1 million ($0.3 million ($nil for Q1/05 and Q4/05).5 million in Q4/05 ). The playback number is: 1-877-289-8525 or
416-640-1917, reservation number 21151232. MIGENIX is headquartered in Vancouver, British Columbia, Canada
with US operations in San Diego, California .
Tel: (604) 221-9666 Investor Relations Group
Extension 241 Tel: (212) 825-3210
Theproteam@aol.S.

xeroderma nyhan

The long-term outcome of children conceived by IVF is unknown."
In Kentucky, State Representative Paul Marcotte introduced a similar
resolution "in honor of my 9-year-old grandson" who has Friedreich's Ataxia. A $9. Research and development
expenses include: (1) clinical development program costs; (2) personnel costs;
(3) patent-related costs; and (4) other costs.8 million ($0.

General and Corporate Expenses

General and corporate expenses decreased slightly in Q1/06 to
$0. Please telephone 1-800 -814-3911 (U.
-------------------------------------------------------------------------

Selected Financial Highlights

BALANCE SHEETS July 31 , April 30,
Unaudited - In Thousands of Canadian dollars 2005 2005
-------------------------------------------------------------------------
Assets
Cash and cash equivalents $ 5,759 $ 1,181
Short-term investments 10,232 10,846
Other current assets 418 1,426
---------------------------------------------------------------- ---------
Total current assets $ 16,409 $ 13,453
Long -term investments 1 1
Other assets - 186
Capital assets 1,082 1,142
Intangible assets 6,239 6,424
-------------------------------------------------------------------------
Total assets $ 23,731 $ 21,206
------------------------- ------------------------------------------------

Liabilities and Shareholders' Equity
Accounts payable and accrued liabilities $ 2,245 $ 2,595
Current portion of capital lease obligation 53 63
-------------------------------------- -----------------------------------
Total current liabilities $ 2,298 $ 2,658

Capital lease obligation - 6
Preferred shares - -
---------------- ---------------------------------------------------------
Total liabilities $ 2,298 $ 2,664
------------------------------------------------------- ------------------

Shareholders' equity 21,433 18,542
-------------------------------------------------------------------------
Total liabilities and shareholders' equity $ 23,731 $ 21,206
------------------------------------- ------------------------------------

STATEMENTS OF LOSS AND DEFICIT Three months ended
Unaudited - In Thousands of Canadian dollars July 31,
(except per share amounts) 2005 2004
(restated(1))
----------------------------------------------------- --------------------
Revenue
Research and development collaboration 269 -
-------------------------------------------------------------------------
$ 269 $ -
------------------- ------------------------------------------------------
Expenses
Research and development 2,029 2,320
General and corporate 827 911
Amortization 247 120
-------------------------------------------------------------------------
$ 3,103 $ 3,351
------------------------- ------------------------------------------------

Operating loss $ (2,834) $ (3,351)

Interest income 80 112
Foreign exchange (loss) gain (18) 6
-------------------------------------------------------------------------
Loss for the period $ (2,772) $ (3,233)

Deficit, beginning of period (97,315) (86,771)
----------------------------------------------------- --------------------
Deficit, end of period $ (100,087) $ (90,004 )
-------------------------------------------------------------------------

Basic and diluted loss per common share $ (0.

amaurosis stickler

However a
nine-fold increase in imprinted gene disorders , such as Beckwith Wiedemann
Syndrome, has been reported.
"We speculate that IVF has altered imprinting in these children and that
aspects of this alteration are manifested in growth and lipid regulating
genes, resulting in differences between the two groups," said Dr. Additional symptoms frequently include severe heart disease,
scoliosis, and diabetes.
http://www. portion of the study
is being conducted under a Special Protocol Assessment reached between the
U.1 million (April 30, 2005:
$10. MIGENIX will need to raise additional funds in
support of its operations and there is no assurance that such funds can be
obtained. PT)
to discuss this announcement. number of common shares
outstanding (000's) 69,440 53,635
-------------------------------------------------------------------------

STATEMENTS OF CASH FLOWS
Unaudited - In Thousands of Canadian dollars
-------------------------- -----------------------------------------------
Loss for the period $ (2,772) $ (3,233)
Loss not affecting cash:
Amortization 247 120
Stock-based compensation 105 96
Changes in non-cash working capital items
relating to operating activities 736 512
Deferred revenue - 267
---------------------------------------------------------------- ---------
Cash used in operating activities $ (1,684) $ (2,238)
-- -----------------------------------------------------------------------

Issuance of common shares, net of issue costs 5,743 -
Proceeds on exercise of stock options - 1
Repayment of capital lease obligation (16 ) (14)
-------------------------------------------------------------------------
Cash provided by (used in) financing activities $ 5,727 $ (13)
---------------- ---------------------------------------------------------

Funds from short-term investments 561 2,248
Purchases of capital assets (26) (123)
Other asset expenditures - (463 )
-------------------------------------------------------------------------
Cash provided by investing activities $ 535 $ 1,662
--------------------------------- ----------------------------------------

Increase (decrease) in cash and cash equivalents $ 4,578 $ (589)
Cash and cash equivalents, beginning of period 1,181 4 ,382
-------------------------------------------------------------------------
Cash and cash equivalents, end of period $ 5,759 $ 3,793
---------------------------- ---------------------------------------------
(1) Restated pursuant to change in accounting policy for patent costs

About MIGENIX

MIGENIX is committed to advancing therapy, improving health, and
enriching life by developing and commercializing drugs in the areas of
infectious and degenerative diseases.D.
President + CEO

CONTACTS
Jonathan Burke, Gino de Jesus or
MIGENIX Inc.